Boehringer Ingelheim

Biotech’s IPO Comeback; Trump’s Tariff Loophole for Pharma

Novo's Double Departures: As GLP-1 Luminary Retires, an Obesity Leader Goes to Boehringer Ingelheim

Survodutide Shows 16.6% Weight Loss in Phase 3 Trial, Boosting Obesity Drug Race

Click Therapeutics Raises $50M and More Funding News

Bringing AI-Driven Protein-Design Tools to Biologists Everywhere

AI Systems Slash Drug Discovery Time, Yield New Cancer and Neurodegenerative Candidates

Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus

STAT+: Boehringer’s Obesity Drug Shows 16.6% Weight Loss; More Data Needed

Boehringer Drug Scores in Rare Kidney Disease FSGS

Makary’s Reforms Will Live on at FDA Even as Leadership Turns Over

Alkermes' Narcolepsy Phase 3 Success; Boehringer's Antibody Deal

Boehringer Ingelheim and Zai Lab Team up for Dual DLL3 Therapy Study

Boehringer Ingelheim Takes Rare Kidney Disease Drug to Phase 3 Despite Puzzling Mid-Stage Data

CMS's Medicare Price Negotiations Start Round Three

Nine Biotech Companies that Could Revolutionize Obesity Treatments

A Deep Dive Into INN Proposed List 134

FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report

What Does 17 Pharma MFN Deals Are Underneath the Press Releases: The Real Primary Source Stack, the GLP1 Numbers, TrumpRX Plumbing, and Where the New Adjudication Layer Gets Monetized

MetricStream Appoints Neha Srivastava as SVP-HR

Boehringer Targets AI-Driven Advances in Disease Research

Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug

Boehringer, Zealand’s Obesity Drug ‘More Akin’ to Novo’s Wegovy in Phase 3

Are We Ready for the Next Wave of Proximity Degraders?

Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials

Cipla Secures FDA Approval for Generic Nintedanib Capsules, Expanding U.S. IPF Portfolio

Hospitals Could Earn More for Buying US-Made Drugs, CMS Proposes

FDA Grants Full Approval to Travere’s FILSPARI for FSGS, Unlocking $2B Market

UK Knowledge Quarter Welcomes Boehringer Ingelheim AI Accelerator

Early Intervention an Unmet Need in Diabetic Macular Edema

Dual-Agonist Survodutide Shows Significant Weight Loss in Phase III Obesity Trial

Boehringer Ingelheim to Expand Its AI Footprint in UK, in £150M Investment

Biopharma Catalysts in Q2 2026 Signal High-Profile Approval Decisions and Rising Competition

Supreme Court Declines to Hear Drugmakers' Challenge to Price Negotiations

Boehringer Signs €1bn+ Deal for Simcere IBD Candidate

MIT Scientists Discover Millions of “Silent Synapses” In the Adult Brain

Boehringer Ingelheim Introduces LENZELTA®: A New Vaccine Advancing Mastitis Prevention in Dairy Cows

Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy

Japan’s MHLW Approves Boehringer’s Jascayd for IPF and PPF

The BioPharm Brief: AI, Immunology, and Regulatory Momentum

VIDEO: ‘New Era of Oral Therapies’ on Horizon in Psoriasis

10 Obesity Drug Companies to Watch in 2026

Infex Chases After Insmed with Bronchiectasis Trial Win

Pig Liver Xenotransplant Shows Promise, but More Work Remains

How Supply Chain Becomes a Growth Partner in Pharma

Boehringer Ingelheim Gets an IBD Bispecific From Shanghai-Based Simcere

Maryland Board Caps Ozempic at $274 per Month, Second State Drug‑Cost Limit

Oral Wegovy Backed by CHMP at May Meeting

The Pink Pill: New Documentary Exposes the Long Battle to Bring Addyi — the First Libido Drug for Women — to Market

‘Orchestra of Therapies’ Required for Most SSc Patients

Boehringer’s Next‑Gen GLP‑1 Survodutide Cuts Weight 16% in Phase 3 Trial

Click Therapeutics Raises $50M Series D to Commercialize CT‑155 Digital Therapeutic

Boehringer Ingelheim to Acquire IBD Bispecific From Simcere for €42M

Boehringer Ingelheim Invests $50M in Click Therapeutics to Commercialize CT‑155 Schizophrenia Digital Therapeutic

Smartbax Closes €4.7M First Tranche of Pre-Series A Round